로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Cell > PD-1 > SCJUR-STF064

Human PD-1 (Luc) Jurkat Reporter Cell

Order Now

  1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
  2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
  3. Comprehensive application data to support assay development and validation
  4. Full tracible record, stringent quality control and validated cell passage stability
  5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
  6. Global commercial license assistance whenever regulatory filing is required
  • Description
    The Human PD-1 (Luc) Jurkat Reporter Cell was engineered to not only express the NFAT response element driving luciferase expressing systems, but also express the receptor full length human PD-1 (Uniprot: Q15116), which can use to evaluate the potency of PD-1 blockade. When cocultured with target cells expressing human PD-L1, the PD-1/PD-L1 interaction inhibits TCR signaling and NFAT-mediated luminescence. Blocking the PD-1/PD-L1 interaction by either anti-PD-1 or anti-PD-L1 antibodies releases the inhibitory signal and results in TCR activation and NFAT-mediated luminescence.
  • Application

    • Screen for anti-human PD-1 or anti-human PD-L1 antibody.

     PD-1 Assay Principles

  • Growth Properties
    Suspension
  • Selection Marker
    Puromycin (5 μg/mL) + Hygromycin B (20 μg/mL)
  • Complete Growth Medium
    RPMI-1640 + 10% FBS
  • Freeze Medium
    Serum-free cell cryopreservation medium
  • Quantity
    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.

Receptor Assay
 PD-1 FACS

Expression analysis of human PD-1 on Human PD-1 (Luc) Jurkat Reporter Cell by FACS.
Cell surface staining was performed on Human PD-1 (Luc) Jurkat Reporter Cell or negative control cell using FITC-labeled anti-human PD-1 antibody.

Application
 PD-1 APPLICATION

Blocking activity of anti-human PD-1 antibody (RLU).
This reporter cell was incubated with serial dilutions of Anti-human PD-1 Antibody in the presence of target cells expressing human PD-L1. The EC50 was approximately 1.189 μg/mL.

 PD-1 APPLICATION

Blocking activity of anti-human PD-1 antibody (FOLD).
This reporter cell was incubated with serial dilutions of Anti-human PD-1 Antibody in the presence of target cells expressing human PD-L1. The max induction fold was approximately 22.47.

Passage Stability
 PD-1 PASSAGE

Passage stability analysis by Signaling Bioassay.
The continuously growing Human PD-1 (Luc) Jurkat Reporter Cell was stimulated with serial dilutions of Anti-human PD-1 antibody in the presence of target cells expressing human PD-L1. Anti-human PD-1 antibody stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 12-36.

Please contact us if you are interested in related cell pool service.

  • Limited Use&License Disclosure

    BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.

    1. If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
    2. Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
    3. This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use . You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    4. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    5. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    6. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.
  • Clinical and Translational Updates

Comments (0)


ETA of in-stock products: 2 business days

Price(USD) : $10550.00

Drug Development Status

  • Number of Launched Drugs:17 Details
  • Number of Drugs in Clinical Trials:141 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop